DYN
Dyne Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 2 ▲ Dyne Therapeutics reported positive topline results from the Phase 1…
- Mar 8 ▲ Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER…
- Jun 22 to Jul 7 ▼ 8 days of insider sells: $39.7M by 3 insiders, avg $21.88
- Jul 27 ▼ 1 insider sell $6.7M at $25.51
- Aug 13 to Aug 14 ▼ 2 days of insider sells: $65.4M by 5 insiders, avg $25.20
- Sep 4 to Sep 8 ▼ 2 days of insider sells: $247.8K by 3 insiders, avg $21.04
- Sep 8 FDA: Dyne Therapeutics to Present Additional One-Year Clinical…
- Sep 29 ▲ Dyne Therapeutics presented additional one-year efficacy data from t…
- Sep 29 FDA: Dyne Therapeutics Announces Additional One-Year Clinical D…
- Oct 2 ▲ 1 insider buy $40.0K at $16.00
- Oct 22 Activist stake: Dyne Therapeutics Reports Inducement Grants Under Nasdaq L…
- Oct 28 ▼ Oppenheimer downgrades
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $40.0K at an average $16.00. 6 insiders sold $112.1M.
- InstitutionsMIXED
Q2 2026: 19 added (0 new), 13 trimmed or exited.
- AnalystsBULLISH
18 of 21 rate it Buy or better. Median target $36.00 (+116%).
- EstimatesFALLING
Current-quarter EPS estimate −$0.871 → −$1.023 over 90 days. 1 up, 4 down in 30 days.
- Short sellersSTEADY
Short interest −4.3% to 24.38M shares. 10.8 days to cover, ≈13.0% of shares.
- TrendRANGE
1% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $248.9M |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $87.4M |
| BANK OF AMERICA CORP /DE/ | ADD | $49.6M |
| GOLDMAN SACHS GROUP INC | ADD | $47.9M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | $43.2M |
| MARSHALL WACE, LLP | DOUBLED | $33.1M |
| CITADEL ADVISORS LLC | DOUBLED | $25.4M |
| Fiera Capital Corp | TRIM | $17.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is inside the target range. Median implies +116%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 28, 2026 | Oppenheimer DOWNGRADE | Perform |
| Sep 30, 2026 | Chardan Capital MAINTAIN | Buy |
| Sep 30, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Sep 29, 2026 | Piper Sandler REITERATE | Overweight |
| Sep 9, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Sep 9, 2026 | JP Morgan DOWNGRADE | Underweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kerr Douglas Head of R&D and CMO Oct 20, 2026 | AWARD | 12,000 sh |
Kerr Douglas Head of R&D and CMO Oct 20, 2026 | AWARD | 8,000 sh |
Posner Brian S Director Oct 2, 2026 | BUY | $40.0K |
Cox John CEO & President Sep 8, 2026 | SELL | $106.8K |
Kerr Douglas Chief Medical Officer Sep 8, 2026 | SELL | $24.4K |
Friedl-Naderer Johanna Chief Commercial Officer Sep 8, 2026 | SELL | $3.5K |
Kerr Douglas Chief Medical Officer Sep 4, 2026 | SELL | $91.2K |
Friedl-Naderer Johanna Chief Commercial Officer Sep 4, 2026 | SELL | $21.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.02 | -$1.12–-$0.85 | -14.8% | $0.00 |
| Next Q | -$1.00 | -$1.08–-$0.91 | -19.2% | $3.0M |
| Current FY | -$3.91 | -$4.00–-$3.83 | -10.3% | $0.00 |
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
46 filings · 8 press releases · 3 bullish · 8 bearish · 2 mixed · 33 neutral- NEUTRAL SC 13GNov 16, 2026
Wellington Management Group LLP disclosed a 5.7% passive stake in Dyne Therapeutics as of September 30, 2026, via a new Schedule 13G filing. The stake of approximately 10.58 million shares represents a notable institutional position but carries no activist intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 13, 2026
Director Douglas Kerr filed a Form 144 notice of intent to sell 2,604 shares of Dyne Therapeutics…
The filing is a routine insider notice with minimal market impact. Monitor for any subsequent Form 4 filings to confirm execution, but no material read-through for the stock.
- NEUTRAL 144Nov 13, 2026
John Cox, an officer of Dyne Therapeutics, filed a Form 144 notice of intent to sell 5,513 shares…
The filing is a routine Form 144 tied to RSU vesting, not a discretionary sale. The small size relative to market cap and the officer's role suggest no material signal. Monitor for any subsequent…
- NEUTRAL 8-KNov 5, 2026
The BLA for z-rostudirsen in DMD is under FDA priority review with a PDUFA date of January 21…
The key catalyst is the January 21, 2027 PDUFA date for z-rostudirsen; approval would mark Dyne's first commercial product. The wider net loss and increased spending on manufacturing and Phase 3…
All DYN filing & press-release reports (54)
- SC 13G reportNov 16, 2026
- 144 reportNov 13, 2026
- 144 reportNov 13, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- INST-CLUSTER reportOct 29, 2026
- PRESS-RELEASE reportOct 22, 2026
- INST-CLUSTER reportOct 12, 2026
- PRESS-RELEASE reportSep 29, 2026
- CLUSTER reportSep 8, 2026
- CLUSTER reportAug 17, 2026
- 144 reportAug 14, 2026
- 144 reportAug 13, 2026
- 144 reportAug 13, 2026
- 144 reportAug 13, 2026
- PRESS-RELEASE reportJul 29, 2026
- PRESS-RELEASE reportJul 21, 2026
- 8-K reportJul 20, 2026
- 144 reportJun 25, 2026
- 144 reportJun 26, 2026
- CLUSTER reportJun 30, 2026
- 144 reportJun 29, 2026
- 3 reportJun 23, 2026
- 8-K reportJun 22, 2026
- CLUSTER reportJun 17, 2026
- 8-K reportJun 17, 2026
- INST-CLUSTER reportJun 12, 2026
- 8-K reportJun 3, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportMay 20, 2026
- PRESS-RELEASE reportMay 20, 2026
- 144 reportMay 13, 2026
- 144 reportMay 13, 2026
- 8-K reportMay 11, 2026
- 144 reportMay 6, 2026
- 144 reportMay 6, 2026
- 144 reportMay 4, 2026
- 144 reportMay 4, 2026
- 144 reportMay 4, 2026
- CLUSTER reportApr 22, 2026
- CLUSTER reportApr 22, 2026
- 144 reportApr 28, 2026
- CLUSTER reportApr 22, 2026
- 144 reportApr 24, 2026
- DEFA14A reportApr 23, 2026
- CLUSTER reportApr 21, 2026
- 144 reportApr 20, 2026
- 144 reportApr 20, 2026
- CLUSTER reportMar 30, 2026
- 144 reportApr 1, 2026
- CLUSTER reportMar 5, 2026
- PRESS-RELEASE reportMar 8, 2026
- CLUSTER reportMar 5, 2026
- PRESS-RELEASE reportMar 2, 2026